RxDoctor Payments Data

Michelle Jenkins, MD

Family Medicine · Cumming, GANPI 1881677458

Payments from drug & device makers

$13,587in general payments, 2019–2025

Across 755 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • Pfizer$1K
  • AstraZeneca$1K
  • Boehringer Ingelheim$726
  • plus $6K from 48 others

What the payments were for

  • Food & beverage$13,38799%
  • Education$2001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,587 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$372,201
Medicare patients
770
Services billed
5,955

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin127$142,217
MounjaroTirzepatide74$89,215
OzempicSemaglutide58$87,552
EliquisApixaban70$80,645
JanuviaSitagliptin Phosphate52$63,302
TrulicityDulaglutide38$52,140
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$40,640
MyrbetriqMirabegron50$34,150
Breo ElliptaFluticasone/Vilanterol28$23,341
XareltoRivaroxaban14$22,787
FarxigaDapagliflozin Propanediol25$19,870
ArexvyRsvpref3 Antigen/As01e/Pf43$12,919
Levothyroxine Sodium654$6,228
SynthroidLevothyroxine Sodium67$6,050
SymbicortBudesonide/Formoterol Fumarate18$4,233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$726$142,217127 claims
Lilly USA, LLCMounjaro, Trulicity$1,258$141,355112 claims
Novo NordiskOzempic$1,406$87,55258 claims
PfizerEliquis$1,249$80,64570 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy$215$76,899125 claims
MerckJanuvia$364$63,30252 claims
Astellas Pharma US IncMyrbetriq$569$34,15050 claims
AstraZenecaFarxiga, Symbicort$1,143$24,10343 claims
Johnson & JohnsonXarelto$429$22,78714 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$29$6,228654 claims
AbbVieSynthroid$1,541$6,05067 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Cumming

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →